Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 735 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Biliary Diseases Clear all

Conditions: Primary Sclerosing Cholangitis, Inflammatory Bowel Disease
Interventions: Vancomycin; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Biliary Tract Disease
Interventions: Cholangiopancreatoscopy; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Primary Sclerosing Cholangitis
Interventions: Hymecromone; Drug
Lead sponsor: Aparna Goel; Other
Eligibility: 14 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Redwood City, California • Stanford, California

Conditions: Intrahepatic Cholestasis of Pregnancy
Interventions: Volixibat, Placebo; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 4 more

Conditions: Pancreatic Disease, Pancreatic Cancer, Pancreatic Cyst, Gastrointestinal Tumor, Bile Duct Diseases, Bile Duct Cancer, Lymph Node Disease, Submucosal Tumor of Gastrointestinal Tract, Gastrointestinal Cancer
Interventions: Endoscopic ultrasound examination; Device
Lead sponsor: Orlando Health, Inc.; Other
Eligibility: 18 Years to 100 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Pruritus
Interventions: EP547, Placebo; Drug
Lead sponsor: Escient Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 21
States / cities: Birmingham, Alabama • Phoenix, Arizona • Coronado, California + 17 more

Conditions: Ampulla of Vater Adenocarcinoma, Gallbladder Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Stage III Ampulla of Vater Cancer, Stage III Intrahepatic Cholangiocarcinoma, Stage III Pancreatic Cancer, Stage IIIA Gallbladder Cancer, Stage IIIA Hilar Cholangiocarcinoma, Stage IIIB Gallbladder Cancer, Stage IIIB Hilar Cholangiocarcinoma, Stage IV Ampulla of Vater Cancer, Stage IVA Gallbladder Cancer, Stage IVA Hilar Cholangiocarcinoma, Stage IVA Intrahepatic Cholangiocarcinoma, Stage IVA Pancreatic Cancer, Stage IVB Gallbladder Cancer, Stage IVB Hilar Cholangiocarcinoma, Stage IVB Intrahepatic Cholangiocarcinoma, Stage IVB Pancreatic Cancer
Interventions: ADH-1, Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Necrotizing Enterocolitis, Digestive System Abnormalities, Cholestasis
Interventions: remove Mn from PN if evidence of increased brain Mn on MRI; Dietary Supplement
Lead sponsor: Vanderbilt University; Other
Eligibility: 30 Days to 12 Months
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Primary Sclerosing Cholangitis
Interventions: Dietary Intervention; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cholecystitis, Hepatocellular Carcinoma, Liver Metastases
Interventions: Indocyanine green, PINPOINT Endoscopic Fluorescence; Drug · Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Cholecystitis, Endometriosis, Bowel Obstruction, Fibroids, Prostate Cancer, Chronic Kidney Disease, Uterine Prolapse
Interventions: Deep to Moderate NMB, Moderate to Deep NMB, Rocuronium; Procedure · Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Parenteral Nutrition Associated Liver Disease
Interventions: Omegaven; Drug
Lead sponsor: St. Luke's Health System, Boise, Idaho; Other
Eligibility: Up to 17 Years
U.S. locations: 1
States / cities: Boise, Idaho

Conditions: Gastric Cancer, Colorectal Cancer, Pancreatic Cancer, Biliary Cancer
Interventions: AbGn-107; Biological
Lead sponsor: AbGenomics B.V Taiwan Branch; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 6
States / cities: Phoenix, Arizona • San Francisco, California • Boston, Massachusetts + 1 more

Conditions: Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
Interventions: tucatinib, trastuzumab, fulvestrant; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 76
States / cities: Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 47 more

Conditions: Gallstones, Appendicitis, Pelvic Pain
Interventions: Endoscopic Cholecystectomy, Endoscopic Appendectomy, Endoscopic Peritoneoscopy; Procedure
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 18 Years to 60 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Unresectable Pancreatic Cancer, Cholangiocarcinoma Non-resectable
Interventions: Radiofrequency Ablation using EndoHPB Probe, Stenting only; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Biliary Cholangitis
Interventions: Mindfulness Based Intervention; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Primary Biliary Cholangitis, Compensated Cirrhosis
Interventions: K-808; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 6
States / cities: Chandler, Arizona • Coronado, California • Indianapolis, Indiana + 2 more

Conditions: Cystic Fibrosis, Gastrointestinal Diseases, Cholestasis
Interventions: ursodiol; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 4 Months and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Biliary Tract Cancer, Gallbladder Cancer
Interventions: Panitumumab, oxaliplatin, gemcitabine; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 100 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Boston, Massachusetts • Rochester, New York

Conditions: Biliary Tract Cancer
Interventions: Irinotecan & Capecitabine; Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Biliary Tract Neoplasms, Cholangiocarcinoma, Bile Duct Cancer, Liver Cancer, Gallbladder Cancer
Interventions: Pembrolizumab (MK-3475), Oxaliplatin, Capecitabine; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cholecystitis, Acute, Biliary Diseases
Interventions: Repeat biliary point of care ultrasound; Diagnostic Test
Lead sponsor: WellSpan Health; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: York, Pennsylvania

Conditions: Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma, Advanced Esophageal Carcinoma, Metastatic Esophageal Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Esophageal Carcinoma, Locally Advanced Gastric Carcinoma, Metastatic Colorectal Carcinoma (mCRC), Advanced Lung Carcinoma, Locally Advanced Hepatocellular Carcinoma
Interventions: Olanzapine, Placebo Administration, Questionnaire Administration; Drug · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis

Clinical Utility of ERCP Guided Cholangiopancreatoscopy With the SpyGlass DS

Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.

A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)

EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope

Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer

Brain Manganese Deposition in High Risk Neonates

A Pilot Study Examining Diet in Primary Sclerosing Cholangitis

Low Dose ICG for Biliary Tract and Tumor Imaging

Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery

Omegaven Expanded Access Protocol

A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Hybrid Transvaginal-Transabdominal Endoscopic Surgery

RFA RCT for Pancreatic or Bile Duct Cancer

Mindfulness - Based Intervention in the Treatment of Fatigue in Patients With Primary Biliary Cholangitis

A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis.

Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease

Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer

Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

Repeat Biliary Point of Care Ultrasound for Detecting Early Acute Cholecystitis

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer